Modified Ambroxol Derivatives

About Zywie

Zywie is a private, preclinical-stage biotech founded in 2021 and based in San Diego, targeting Lysosomal Storage Diseases (LSDs) and related neurodegenerative disorders. Its core technology involves developing proprietary, modified versions of Ambroxol, a molecule with dual mechanisms of action as a pharmacological chaperone and a TFEB activator to enhance cellular clearance pathways. The company is led by veteran biotech entrepreneur Robert F. Johnston and is supported by a scientific advisory board with deep expertise in lysosomal biology and protein folding diseases. Zywie is currently in the pre-revenue, drug discovery and development phase.

Therapeutic Areas